In this part of their Pharmaceutical Executive video interview, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, explain how their company guarantees the authenticity of the medications it dispenses, and the measures are in place to prevent counterfeit drugs from entering their supply chain.
Peter Ax: So you know, UpScript really works with pharma companies to bring drugs directly to the consumer, and when we do that, in most cases, we use third party fulfillment sources like an Amazon, like a hub services company or a specialty pharmacy company. But when we do supply the medication ourselves through our own captive pharmacy operation, we pedigree every single pill that comes into our system, every single device, every single medication, it's all pedigree back to the original source of who manufactured it, where it was manufactured, when it was manufactured, and that's an obligation of pharmacies, frankly, so if you're a properly licensed pharmacy, as we have in in our operations, you're assured that that that medication is legitimate, branded properly, etc., and that's true for any properly licensed pharmacy, they should be adhering to that pedigree.
George Jones: We're in the process of preparing for in kind of 95% there the Federal Supply Chain Security Act, so we'll be able to track, track the product, kind of from birth to grave, if you will. We also only buy from either the major wholesalers or directly from the manufacturer of the products as well. So, you know, all those things help us ensure that we are always, always dispensing kind of legitimate, branded or generic products to patients.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.